SubHero Banner
Text

Orencia® (abatacept) – Expanded indication

March 30, 2017 – The FDA approved Bristol-Myers Squibb’s Orencia (abatacept) injection, for reducing signs and symptoms in patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA).

Download PDF